تدبير الإجهاضات : حالات خاصة

Abstract EN

Afibrinogenemia is a rare bleeding disorder with an estimated prevalence of 1:1,000,000.

It is an autosomal recessive disease resulting of marriages of relatives in an excess of the 3 genes (FGA, FGB, and FGC) fibrinogen play an important role in formation of blood clot being transformed to fibrin via thrombin.

The combination and adhesion of paletes stimulated by ADP is also weak in those patients, but on the other side the combination of paletes stimulated by thrombin and collagen is normal.

The research aims to define the success of replacement therapy and to realize the rate of fibrinogen which is required for the therapy of recurrent miscarriages.

The methods of research were taken by reviewing the clinical features and the management of patients who are suffering of fibrinogenemia.

We already discussed the protective therapy and the pregnancy of those patients.

Results: Five pregnants were noted in different pregnancy ages after the application of therapy.

Conclusions: A fibrinogen concentration must be 60/mg / dl during the pregnancy.

The importance of research: The development of new tests to identify higher risk patients and of safer replacement therapy will improve the management of afibrinogenemia in the future.